Hemophilia disease is a rare inherited bleeding disorder. People with this genetic condition do not produce sufficient clotting factors, which can cause uncontrolled external or internal bleeding.

Over one-third of hemophilia patients experience bleeding episodes and joint damage despite prophylactic therapies, indicating a need for more effective treatments. Data from the Adelphi Hemophilia ...

Nonfactor therapies may reduce costs associated with bleeding-related hospitalizations and use of bypassing agents. One study ...

The novel treatment, partly developed by CHOP, eliminates the need for regular infusions while preventing the ...

Blood clotting represents one of the body’s most elegant and complex protective mechanisms. This intricate process involves numerous proteins working in precise sequence – often described as a ...

Sangamo BioSciences, Inc. (Nasdaq: SGMO), a leader in therapeutic genome editing, announced today that the company and its collaborator, Shire plc (LSE: SHP, NASDAQ: SHPG), have agreed to revise their ...

The clinical trials report on Hemophilia A highlights opportunities in optimizing trial locations, enhancing cost-efficiency, and strategizing investments by offering insights into trial distributions ...

LONDON, Ontario and WINDHAM COUNTY, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (SVA:CA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today ...

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 14, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with ...